TITLE

Vasopressin receptor antagonists

AUTHOR(S)
Greenberg, A.; Verbalis, J. G.
PUB. DATE
June 2006
SOURCE
Kidney International;Jun2006, Vol. 69 Issue 12, p2124
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The first non-peptide vasopressin receptor antagonist (VRA) was recently approved by the United States Food and Drug Administration, and several others are now in late stages of clinical development. Phase 3 trials indicate that these agents predictably reduce urine osmolality, increase electrolyte-free water excretion, and raise serum sodium concentration. They are likely to become a mainstay of treatment of euvolemic and hypervolemic hyponatremia. Although tachyphylaxis to the hydro-osmotic effect of these agents does not appear to occur, their use is accompanied by an increase in thirst, and they do not always eliminate altogether the need for water restriction during treatment of hyponatremia. Experience with use of these agents for treatment of acute, severe, life-threatening hyponatremia as well as chronic hyponatremia is limited. Further studies are needed to determine how they are best used in these situations, but the risk of overly rapid correction of hyponatremia seems low. Results of long-term trials to determine the ability of VRAs to reduce morbidity or mortality in congestive heart failure or to slow the progression of polycystic kidney disease are awaited with great interest.Kidney International (2006) 69, 2124–2130. doi:10.1038/sj.ki.5000432; published online 3 May 2006
ACCESSION #
21091098

 

Related Articles

  • Manufacturer voluntarily pulls Manoplax from the market. Rodman, Morton J.; Hurley, Mary Lou // RN;Jan94, Vol. 57 Issue 1, p93 

    Reports on the withdrawal of the drug flosequinan (Manoplax) from the market by manufacturer Boots. Scrutiny of patient deaths by the Food and Drug Administration; Exacerbation of congestive heart failure symptoms.

  • Vasomedical is pumped by the FDA's turnabout. Schachter, Ken // Long Island Business News (7/1993 to 5/2009);7/26/2002, Vol. 49 Issue 31, p11 

    Focuses on the U.S. Food and Drug Administration's approval of the use of TS-3 from Vasomedical Inc. for treating congestive heart failure. Test conducted regarding the safety and efficacy of the drug; Effects of the medicine on the patient's body; Impact of the move on the operations of...

  • Diabetes Medication Associated with Increased Risk of Heart Problems.  // O&P Business News;4/1/2008, Vol. 17 Issue 7, p71 

    The article highlights the study in the Journal of the American Medical Association on the risks of diabetes medications in the U.S. According to the author, the study shows that there is a significant increased risk of heart attack, congestive heart failure (CHF) and death to older patients...

  • Laboratory and Clinical Aspects of B-Type Natriuretic Peptides. Elm, Ronald J.; Winter, William E. // Archives of Pathology & Laboratory Medicine;Jun2004, Vol. 128 Issue 6, p697 

    The article discusses the laboratory and clinical aspects of b-type natriuretic peptides (BNP). The measurement of BNP concentration in plasma was introduced to the clinical laboratory and approved by the U.S. Food and Drug Administration approximately 3

  • Is your patient still using rosiglitazone? Gov-Ari, Hanna K.; Stevermer, James J. // Clinician Reviews;Aug2011, Vol. 21 Issue 8, p30 

    The article reports that doctors have stopped prescribing rosiglitazone when a study linked it to an elevated myocardial infarction (MI) risk. That it is not advised to switch to pioglitazone instead of initiating rosiglitazone therapy for patients with diabetes is pointed out. Although removing...

  • First selective aldosterone-blocker now approved for CHF. LoBuono, Charlotte // Drug Topics;11/3/2003, Vol. 147 Issue 21, p28 

    Reports on the approval given by the U.S. Food and Drug Administration for the administration of eplerenone for treatment of congestive heart failure. Improvement of the survival of stable patients with left ventricular systolic dysfunction; Development of the drug Inspra from Pfizer Inc.;...

  • Major drugs for heart failure, obesity pass FDA hurdles.  // Medical Marketing & Media;Jul97, Vol. 32 Issue 7, p16 

    Reports on the US Food & Drug Administration's (FDA) approval of Coreg, a potent new drug for treatment of congestive heart failure. Previous approval of the drug for the treatment of hypertension; Co-marketing of Coreg by Smith-Kline Beecham and Boehringer Mannheim; FDA advisory committee's...

  • The Rise And Fall Of Natrecor For Congestive Heart Failure: Implications For Drug Policy. Kesselheim, Aaron S.; Fischer, Michael A.; Avorn, Jerry // Health Affairs;Jul/Aug2006, Vol. 25 Issue 4, p1095 

    Recent revelations of unexpected side effects of widely prescribed medications have raised questions about several aspects of U.S. drug policy, from initial Food and Drug Administration (FDA) approval to promotion by manufacturers and prescribing by physicians. One prominent example is...

  • Two New Treatments for Congestive Heart Failure.  // FDA Consumer;Nov/Dec2001, Vol. 35 Issue 6, p3 

    Reports on the approval of two treatments for congestive heart failure by the U.S. Food and Drug Administration. Side effect of Natrecor, a drug for dilating veins and arteries; Condition required for people with congestive heart failure to have a biventricular pacemaker; Components of the...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics